Table 1.

Cohort Clinical and Imaging Demographics

Patient #	Age/Sex	Initial Diagnosis	Pembrolizumab Duration (Wks)	SUVmean	SUVmax	SUVR	HV (mL)	Enhancing Volume (mL)	HF (%)	Clinical Outcome at the Time of FMISO PET	Progression-Free Survival (Days)
1	39/M	IDH wildtype, MGMT unmethylated	58	1.34	1.54	0.96	0	0.7	0	PSP at day 450 based on mRANO	574 days based on biopsy at the time of subsequent progression
2	52/W	IDH mutated, MGMT methylated	148	1.74	2.31	0.99	0.21	4.0	5	PSP at day 973 based on mRANO	1095 based on mRANO with subsequent progression
3	73/M	IDH wildtype, MGMT methylated	51	2.41	3.94	1.12	1.44	14.2	10	PSP at day 393 based on biopsy	429 days as a result of perioperative death
4	59/M	IDH wildtype, MGMT unmethylated	11	1.80	3.70	1.14	1.47	6.07	24	PSP at day 92 based on biopsy	231 days based on mRANO with subsequent progression
5	73/M	IDH wildtype, MGMT methylated	41	2.14	4.38	1.46	12.80	7.2	178	Recurrent tumor at day 278 based on biopsy	292 days based on biopsy
6	43/M	IDH wildtype, MGMT methylated	40	1.72	2.84	1.15	1.38	1.62	85	Recurrent tumor at day 346 based on mRANO	399 based on mRANO

Wks, weeks; IDH, isocitrate dehydrogenase; MGMT, O-6-Methylguanine-DNA methyltransferase; SUV_mean/max, mean or maximum standard uptake value within the region of interest; SUVR, standard uptake value ratio; HV, hypoxic volume is defined by values >1.2× the normal cerebellum; enhancing volume, the volume of gadolinium-induced T1 shortening; HF, hypoxic fraction—the ratio of hypoxic volume to T1-weighted gadolinium-enhancing volume. Clinical outcome at the time of presumed progression FMISO PET examination defined by surgical tissue sampling or modified RANO (mRANO) criteria. PSP, pseudoprogression. Progression-free survival, time from surgical resection date to date of clinical outcome; recurrent tumor.